(Q37550588)

English

Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer

scientific article published on 04 June 2016

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

21 August 2017

Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer (English)

1 reference

Europe PubMed Central

21 August 2017

0 references

prostate cancer

1 reference

based on heuristic

inferred from title

Hebert Alberto Vargas

6

object named as

Hebert A Vargas

1 reference

Europe PubMed Central

21 August 2017

author name string

Howard I Scher

1

1 reference

Europe PubMed Central

21 August 2017

David Lu

2

1 reference

Europe PubMed Central

21 August 2017

Nicole A Schreiber

3

1 reference

Europe PubMed Central

21 August 2017

Jessica Louw

4

1 reference

Europe PubMed Central

21 August 2017

Ryon P Graf

5

1 reference

Europe PubMed Central

21 August 2017

Ann Johnson

7

1 reference

Europe PubMed Central

21 August 2017

Adam Jendrisak

8

1 reference

Europe PubMed Central

21 August 2017

Richard Bambury

9

1 reference

Europe PubMed Central

21 August 2017

Daniel Danila

10

1 reference

Europe PubMed Central

21 August 2017

Brigit McLaughlin

11

1 reference

Europe PubMed Central

21 August 2017

Justin Wahl

12

1 reference

Europe PubMed Central

21 August 2017

Stephanie B Greene

13

1 reference

Europe PubMed Central

21 August 2017

Glenn Heller

14

1 reference

Europe PubMed Central

21 August 2017

Dena Marrinucci

15

1 reference

Europe PubMed Central

21 August 2017

Martin Fleisher

16

1 reference

Europe PubMed Central

21 August 2017

Ryan Dittamore

17

1 reference

Europe PubMed Central

21 August 2017

publication date

4 June 2016

1 reference

Europe PubMed Central

21 August 2017

1 reference

Europe PubMed Central

21 August 2017

2

1 reference

Europe PubMed Central

21 August 2017

1441-1449

1 reference

Europe PubMed Central

21 August 2017

11

1 reference

Europe PubMed Central

21 August 2017

Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5206761

23 August 2017

PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5206761

23 August 2017

Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5206761

23 August 2017

Constitutively active AR-V7 plays an essential role in the development and progression of castration-resistant prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5206761

23 August 2017

AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5206761

23 August 2017

Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5206761

23 August 2017

Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5206761

23 August 2017

Androgen receptor splice variant AR3 promotes prostate cancer via modulating expression of autocrine/paracrine factors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5206761

23 August 2017

Population-based study on use of chemotherapy in men with castration resistant prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5206761

23 August 2017

Fluid biopsy in patients with metastatic prostate, pancreatic and breast cancers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5206761

23 August 2017

Evaluating the value of number of cycles of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5206761

23 August 2017

Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5206761

23 August 2017

A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5206761

23 August 2017

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5206761

23 August 2017

Biology, detection, and clinical implications of circulating tumor cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5206761

6 September 2017

Circulating tumor cells: a multifunctional biomarker

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5206761

6 September 2017

Molecular analysis of circulating tumour cells-biology and biomarkers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5206761

6 September 2017

Validation and clinical utility of prostate cancer biomarkers.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5206761

6 September 2017

Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5206761

6 September 2017

Clinical Relevance of Androgen Receptor Splice Variants in Castration-Resistant Prostate Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5206761

14 September 2017

Predicting treatment response in castration-resistant prostate cancer: could androgen receptor variant-7 hold the key?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5206761

25 June 2018

Efficacy of Cabazitaxel in Castration-resistant Prostate Cancer Is Independent of the Presence of AR-V7 in Circulating Tumor Cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5206761

1 September 2018

Serial blood-based analysis of AR-V7 in men with advanced prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5206761

1 September 2018

Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5206761

1 September 2018

Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5206761

1 September 2018

Analytical Validation and Capabilities of the Epic CTC Platform: Enrichment-Free Circulating Tumour Cell Detection and Characterization.

1 reference

https://pubmed.ncbi.nlm.nih.gov/27262168

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1001/JAMAONCOL.2016.1828

1 reference

Europe PubMed Central

21 August 2017

1 reference

Europe PubMed Central

21 August 2017

1 reference

Europe PubMed Central

21 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37550588&oldid=2129856861"